---
schema_version: "secwatch.filing_event.v1"
accession: "0001041024-25-000009"
form_type: "8-K"
ticker: "RMTI"
cik: "0001041024"
company_name: "ROCKWELL MEDICAL, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:43:47.652448+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M

## Summary
- Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.
- Net loss $1.5M vs net income $0.3M in Q2 2024; Adjusted EBITDA -$0.2M vs $1.4M year ago.
- Cash & investments increased to $18.4M, supported by $1.8M operating cash flow.
- Reaffirmed 2025 guidance: net sales $65-70M, gross margin 16-18%, Adj EBITDA -$0.5M to $0.5M.
- Secured multi-year supply agreements with Innovative Renal Care (3-yr) and other providers; >80% customers under long-term contracts.

## SEC filing metadata
- accession: 0001041024-25-000009
- form_type: 8-K
- ticker: RMTI
- cik: 0001041024
- company_name: ROCKWELL MEDICAL, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1041024/000104102425000009/0001041024-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1041024/000104102425000009/rmti-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001041024-25-000009
- JSON: https://secwatch.observer/filing/0001041024-25-000009.json
- Plain text: https://secwatch.observer/filing/0001041024-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.